Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALBIREO PHARMA, INC.

(ALBO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALBIREO PHARMA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

05/06/2021 | 08:37am EDT

Item 2.02 Results of Operations and Financial Condition.

On May 6, 2021, Albireo Pharma, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2021 and providing a business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d)    Exhibits


The following exhibit is furnished with this report:



Exhibit Number                                   Description
  99.1             Press release dated May 6, 2021
104              Cover Page Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses

All news about ALBIREO PHARMA, INC.
06/21ALBIREO PHARMA, INC.  : Change in Directors or Principal Officers, Amendments to..
AQ
06/21Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A39..
GL
06/11ALBIREO PHARMA  : to Showcase New Data at the EASL International Liver Congress ..
AQ
06/10ALBIREO PHARMA  : to Showcase New Data at the EASL International Liver Congress&..
AQ
06/04ALBIREO PHARMA  : New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerabilit..
AQ
06/03New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatmen..
GL
05/26Albireo to Present at Upcoming Jefferies and William Blair Virtual Investor C..
GL
05/25Today on Wall Street: Tech stocks’ return as inflation fears ease
05/25TODAY'S ANALYST RECOMMENDATIONS : Deere, Endeavor, Just Eat, Royal Mail, Visa...
05/24ALBIREO PHARMA  : HC Wainwright Adjusts Albireo Pharma's Price Target to $76 Fro..
MT
More news
Financials (USD)
Sales 2021 13,4 M - -
Net income 2021 -158 M - -
Net cash 2021 117 M - -
P/E ratio 2021 -4,42x
Yield 2021 -
Capitalization 679 M 679 M -
EV / Sales 2021 41,9x
EV / Sales 2022 9,12x
Nbr of Employees 90
Free-Float 84,5%
Chart ALBIREO PHARMA, INC.
Duration : Period :
Albireo Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALBIREO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 71,38 $
Last Close Price 35,35 $
Spread / Highest target 132%
Spread / Average Target 102%
Spread / Lowest Target 61,2%
EPS Revisions
Managers and Directors
NameTitle
Ronald H. W. Cooper President, Chief Executive Officer & Director
Simon John Harford Chief Financial Officer & Treasurer
David John Chiswell Chairman
Jan Peter Mattsson Chief Scientific Officer, Managing Director-Sweden
Patrick Taylor Horn Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALBIREO PHARMA, INC.-5.76%679
GILEAD SCIENCES, INC.15.60%84 469
WUXI APPTEC CO., LTD.24.70%66 143
REGENERON PHARMACEUTICALS10.59%55 327
BIONTECH SE177.34%54 605
VERTEX PHARMACEUTICALS-20.58%48 589